Senex Biotechnology
Columbia · Founded 2002
About Senex Biotechnology
Senex Biotechnology, Inc. engages in discovering and developing therapeutic agents to treat cancer, viral diseases, and age-related diseases. The company offers SNX2 non-cytotoxic molecules compounds that are developed against viral diseases, age-associated diseases, and as add-ons to existing anticancer drug regimens; and SNX9 cyclin-dependent kinase inhibitor pathway inhibitors that are developed for cancer treatment. It offers therapeutic agents to treat cancer and a range of diseases associated with the aging process, such as Alzheimer’s disease, renal disease, atherosclerosis, and arthritis. The company was incorporated in 2002 and is based in Columbia, South Carolina.
Company Facts
- Founded: 2002
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $1.0M
- Last round: Grant (Jan 2025)
- Website: http://senexbio.com
- Phone: +1 803-777-6161
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/senex-biotechnology-47766 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.